Consort Medical plc Stock Rating Reaffirmed by Westhouse Securities (CSRT)
Consort Medical plc (LON:CSRT)‘s stock had its “buy” rating restated by investment analysts at Westhouse Securities in a note issued to investors on Friday. They currently have a GBX 1,100 ($18.67) price objective on the stock. Westhouse Securities’ price objective suggests a potential upside of 20.88% from the company’s current price.
Shares of Consort Medical plc (LON:CSRT) traded up 0.12% on Friday, hitting GBX 911.125. The stock had a trading volume of 17,588 shares. Consort Medical plc has a 52-week low of GBX 773.00 and a 52-week high of GBX 1113.00. The stock’s 50-day moving average is GBX 879.3 and its 200-day moving average is GBX 942.6. The company’s market cap is £262.1 million.
The company also recently announced a dividend, which is scheduled for Friday, October 24th. Investors of record on Wednesday, September 17th will be paid a dividend of GBX 13.35 ($0.23) per share. This represents a dividend yield of 1.53%. The ex-dividend date is Wednesday, September 17th.
Several other analysts have also recently commented on the stock. Analysts at Investec raised their price target on shares of Consort Medical plc from GBX 1,005 ($17.06) to GBX 1,021 ($17.33) in a research note on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Oriel Securities Ltd reiterated a “buy” rating on shares of Consort Medical plc in a research note on Tuesday. They now have a GBX 1,000 ($16.98) price target on the stock. Finally, analysts at N+1 Singer upgraded shares of Consort Medical plc to a “buy” rating in a research note on Tuesday. They now have a GBX 1,020 ($17.31) price target on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of GBX 942.50 ($16.00).
Consort Medical plc is a healthcare company focused on medical technologies. The principal activities of the Company are the design, development and manufacture of specialty medical drug delivery devices and services to the pharmaceutical industry through its Bespak Division and disposable airway management products for critical care settings in hospitals and pre-hospital settings through its King Systems Division.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.